Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Little Green Pharma Ltd. ( (AU:LGP) ).
Little Green Pharma has reported that shareholders of Cannatrek Ltd have overwhelmingly approved the proposed scheme of arrangement for LGP to acquire 100% of Cannatrek’s issued capital. The resolution passed with 96.15% of Cannatrek shareholders present and voting in favour, representing 98.44% of total votes cast, underscoring strong support for the transaction.
The scheme now moves to the Federal Court of Australia for approval at a hearing scheduled for 24 April 2026, with the deal expected to become effective the same day if endorsed. Subject to remaining court and regulatory steps, implementation is targeted for 1 May 2026, positioning LGP to integrate Cannatrek’s operations and potentially enhance its scale and competitiveness in the medicinal cannabis sector.
The most recent analyst rating on (AU:LGP) stock is a Buy with a A$0.18 price target. To see the full list of analyst forecasts on Little Green Pharma Ltd. stock, see the AU:LGP Stock Forecast page.
More about Little Green Pharma Ltd.
Little Green Pharma Ltd is an Australia-based medicinal cannabis company listed on the ASX. The company focuses on cultivating, manufacturing and supplying cannabis-based medicines, and expanding its position in the regulated medical cannabis market through strategic acquisitions and partnerships.
Average Trading Volume: 174,024
Technical Sentiment Signal: Sell
Current Market Cap: A$28.75M
See more insights into LGP stock on TipRanks’ Stock Analysis page.